Update your tester profile Login
  • COVID-19 Prism Update

    Updated on April 1, 2020

    It’s hard to escape news about COVID-19. And with good reason. As an organisation on the front line of finding vaccines for diseases such as Coronavirus, our number one priority is the health and safety of our staff, our clinical trial participants, and the broader community.

    We have answered some of the most frequently asked questions below. If you have any other questions, please get in touch with us at 651-641-2900.

    Is there any impact from Coronavirus (COVID-19) on clinical trials at Nucleus Network sites (Centre for Clinical Studies, Q-Pharm or Prism)?

    Nucleus Network is committed to continuing the vital work undertaken by our clinical trials, with studies continuing to take place.

    While Coronavirus (COVID-19) infection rates in Melbourne, Brisbane and Minnesota remain low, the safety and quality of our trials and facilities is our number one priority. We have introduced strict measures to ensure the safety of all clinical trial participants, visitors and staff, and the quality of our trials.

    In addition to the standard infection control practiced in its three clinics, Nucleus Network has implemented increased risk mitigations associated with Coronavirus (COVID-19). These include:

    • Coronavirus (COVID-19) participant / patient screenings on phone and in-clinic,
    • Regular hand sanitizing using alcohol-based hand rub with 70% alcohol,
    • Every second bed practice to surpass ‘social distancing’ requirements,
    • 6 feet spacing in waiting, dining and recreational areas,
    • Personal Protective Equipment (PPE),  are worn by medical officers, nursing and clinical staff during all participant interactions requiring close physical interaction.
    • Isolation protocols are in place where additional PPE, including goggles, gowns and masks, are worn as appropriate when required for any person displaying high risk symptoms, this includes utilizing dedicated bed and bathroom bays
    • Infection prevention and control procedures in line with World Health Organisation (WHO) and best practice guidelines.

     

     

    These measures go above and beyond recommended clinical practices and provide a gold standard in infection control. We will continue to update and refine its approach to Coronavirus (COVID-19) as more information about the virus continues to be learned.

    Can I still participate in a Nucleus Network clinical trial?

    Yes. We are still recruiting for clinical trials however have implemented an age restriction on participants of 18-59 years (inclusive) to protect older members of our community. We are currently only allowing volunteers from the Minneapolis/St. Paul area.

    The risk of Coronavirus (COVID-19) remains low for all our trial site locations (Melbourne, Brisbane and Minnesota), however, to protect the safety of our participants, staff and trial facilities, we have introduced some additional screening measures.

     

    IMPORTANT

    It is important that you self-isolate if you have knowingly contracted Coronavirus (COVID-19)

    You must answer truthfully when providing information via our online, print and phone channels. Providing false information would equate to an offence.

     

    Phone screening: Participants will be questioned over the phone to determine if they have any risk factors for Coronavirus (COVID-19) exposure.:

    • Travel to or contact with someone who has travelled overseas or out of state within the last 14 days
    • Have stayed or are currently residing in accommodation with high occupant turnover -  This includes dormitory type accommodation within the last 14 days
    • Had direct contact with anyone known to be infected with Coronavirus (COVID-19), and/or
    • Currently have or have had cold / flu symptoms in the past 14 days.

     

    Anyone who answers ‘yes’ to any of the questions above should not visit the unit. If you already have a screening appointment planned, please call 651-641-2900

    Medical screening (in clinic): The above questions will again be asked when the participant presents for their screening visit and the participant will also have their temperature taken and be requested to wash their hands with hand sanitiser upon presentation. However, we ask that if participants do have any cold or flu like symptoms, they inform the clinic and do not attend their medical screening. We will advise the most appropriate action.

    Outpatient visits (in clinic): Active trial participants attending the site for an inpatient or outpatient visit will be required to undergo the same process as described above. It is important for participant safety that all outpatient visits are attended as scheduled during the trial process. However, we ask that if participants do have any cold or flu like symptoms, they inform the clinic and not attend their medical screening. We will advise the most appropriate action.

    Are clinical trials included under the ‘essential travel’ classification?

    Yes. Clinical trials play an imperative, and essential, role in advancing medicines (including vaccines) for the entire community and therefore meet the essential travel requirements.

    Have social distancing measures been implemented at Nucleus Network sites (Centre for Clinical Studies, Q-Pharm or Prism)?

    Yes. Nucleus Network is strictly to social distancing measures with all Nucleus Network sites meeting the 6 ft per person distancing requirements. To ensure we meet, and surpass, this distance we have implemented an ‘every second bed’ policy, where the clinical beds are a minimum 6 feet apart.

    What if I feel unwell after being admitted for a confinement period for a clinical trial?

    Trial participants who begin to experience side effects, changes in their health or have concerns should always speak with the clinical staff / study doctor as soon as possible. In relation to Coronavirus (COVID-19), any fever, cough or other flu like  symptoms noted should immediately be brought to the attention of clinical staff. We will need to medically assess participants and, if necessary, relocate to a different area for further treatment whilst it is established what the cause is.

    Can I still have visitors during my stay at the facility?

    Visitors are usually permitted during long-stay trial admissions. However, to reduce risk of Coronavirus (COVID-19) transmission we will be restricting visitor access at our facilities until further notice. We apologise for this inconvenience and understand the stress this may cause in some cases. We will work with trial participants to find alternative ways to remain in contact with family and friends.

    With your help, we can make a difference in the containment of COVID-19 as together we work on developing the medicines of tomorrow.

    Useful links:

  • Register with Our Database

    Registration form here.

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies.

    Find the registration form here

    If you are interested in speaking with a recruitment member before enrolling, you can schedule a short 10 minute phone call. Schedule

     

     Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

    We will not share or sell this info with any third party.

    Thanks for your interest!

  • BMI Calculator

     BMI stands for "Body Mass Index," and it's a calculation determined by your height and weight. There is almost always a BMI range in Prism's studies. 

    Why does the BMI range exist? To provide an expected norm within which the population of participants will fall.

    Why is there a BMI limit? A participant with a higher BMI may require a greater dose of the study drug and therefore may metabolize the drug differently than a person with a lower BMI.

    Why does the BMI range change from study to study? The range is determined by the study sponsor. The range is based on the type of study, the procedures being done, and the study drug.

     

    Determine your BMI here 

     

     

  • Upcoming Studies

     

     

     Prism has a variety of upcoming studies to participate in: 

    • Inpatient and Outpatient studies for healthy males and females; Age 18-55 years old
    • Liver Impairment 
    • Kidney Impairment 

    To be put on the call list and receive more information, please contact:

    Dayna at daynas@prismresearchinc.com 651-724-5047  or

    Lindsay at lindsayd@prismresearchinc.com 651-368-3360

  • Diagnosed with Kidney or Liver Impairment?

     

     

    KIDNEY IMPAIRMENT:

    Schedule a time to talk: https://bit.ly/2UBaoAE

    Prism Research has upcoming studies for individuals diagnosed with kidney impairment. These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of kidney impairment when compared to volunteers with normal kidney function.

     If you or someone you know has been diagnosed with kidney impairment and are interested in being considered for these studies, please contact Lindsay at 651-368-3360 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Please contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

     

     

    LIVER IMPAIRMENT:

    Schedule a time to talk: https://bit.ly/2DFskFj

    Prism Research has upcoming studies for individuals diagnosed with liver impairment. These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

     

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

     

     

     

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must qualify for a study.
    • Subject may not be referred more than one time.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any prior study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Connect With Us on Social Media and with Prism Text

    PRISM TEXT:

    This texting feature will be a convenient way for the Recruitment Department to TEXT you about upcoming studies. 

    You will be receiving text message from us if you are qualified for a study.

    You are considered OPT-IN unless you tell us to remove you (OPT OUT).

    The texting system is through our secure online database and will not compromise  your phone number. 

     

    SOCIAL MEDIA:

    Have you LIKED Prism Clinical Research on Facebook?

    Have you TAGGED Prism Clinical Research on Twitter?

    Have you FOLLOWED Prism Clinical Research on Instagram?

    Have you SEARCHED 651-368-3360 on Whatsapp?

    Have you WRITTEN A REVIEW on Google? 

    Have you WATCHED on YouTube?

     

    Use the links below:↓

    https://www.facebook.com/PrismResearch/

    https://twitter.com/ResearchPrism

    https://www.instagram.com/prismclinical_research/?hl=en

    https://www.youtube.com/channel/UCozYBk43CpVR9LT54BSQg3g/

  • Kidney Impairment: Clinical Research Study 1811

     

    Purpose:

    • To evaluate the safety and tolerability of an investigational combination of two approved drug in individuals with severe renal impairment compared with individuals without renal impairment.

     

    GENERAL STUDY REQUIREMENTS:

    • Men and Women between the ages of 18 to 75 with a BMI between 17.5 and 40.5kg/m2.
    • Medical conditions and medications must be stable in the opinion of the study doctor.

     

    STUDY DURATION:

    • In Clinic Stay: 5 nights/ 6 days
    • Clinic Visits: 2 Screening visits
    • Follow up Phone call
    • Total study duration is approximately 2 ½ months (including a 28 day screening window)

     

    METHOD OF ADMINISTRATION:

    • IV Administration

     

    STUDY COMPENSATION:

    • Compensation for Study Participation Time Up To: $2,085.00

     

    RECRUITMENT CONTACT:

  • Liver Impairment: Clinical Research Study 1817

    LIVER IMPAIRMENT STUDY

    CLINICAL RESEARCH STUDY: 1817

    PRISM CLINICAL RESEARCH

    PURPOSE:

    • To determine how the investigational drug is absorbed, broken down, and removed from the body in volunteers with abnormal liver function compared to volunteers with normal liver function.

     

    GENERAL STUDY REQUIREMENTS:

    • Men and women between the ages of 18 and 80 years old.
    • Liver Impairment volunteers: must have mild/moderate/severe liver impairment due to diagnosed liver disease.
    • Healthy volunteers: must be healthy; not being evaluated or treated for any medical conditions.

     

    STUDY DURATION:

    • 1 In-Clinic Stay: Lasting 8 nights/ 9 days
    • Clinic Visits: 1(screening)
    • Total Study Duration is Approximately 39 days, including screening

     

    METHOD OF ADMINISTRATION:

    • Oral Administration

     

    STUDY COMPENSATION:

    • Compensation for Study Participation may be provided for time and travel up to $2620.00

     

    RECRUITMENT CONTACT:

  • Liver Impairment: Clinical Research Study 1913

    Liver Impairment Study

    Clinical RESEARCH study: 1913

     

    PRISM RESEARCH

     

    Purpose:

    • To evaluate the safety and tolerability of an investigational drug being developed for treatment of certain types of cancer in healthy volunteers and volunteers who have been diagnosed with different levels of liver impairment.

     

    GENERAL STUDY REQUIREMENTS:

    • Men and women between the ages of 18-75 with a BMI between 18-40
    • Liver impairment volunteers: must have mild/moderate/severe liver impairment documented by medical history
    • Healthy Match volunteers: must be healthy; not being evaluated or treated for any medical conditions

     

    STUDY DURATION:

    • In Clinic Stay: 9 days/8 nights
    • Return Clinic Visits: 2 including screening
    • Total study duration is up to 43 (including screening)

     

    METHOD OF ADMINISTRATION:

    • Oral Dose

     

    STUDY COMPENSATION:

    • Compensation for Study Participation Time Up To: $2740.00

     

    RECRUITMENT CONTACT:

  • Dialysis: Clinical Research Study 2006

     

    Schedule a phone pre-screen:  https://bit.ly/2MmLL71

     

     

     

    Renal Impairment Study: Part 1

    Clinical RESEARCH study: 2006

     

    PRISM RESEARCH

     

    Purpose:

    • To evaluate the safety and tolerability of a single dose medication that is being developed for the prevention of blood clotting complications in volunteers with end stage renal disease who are on dialysis.

     

    GENERAL STUDY REQUIREMENTS:

    • Men and women between the ages of 40-80 with a BMI between 18-42
    • Receiving dialysis treatments at least 3 times per week
    • Must not be taking an anticoagulation therapy
    • Medical conditions and medications must be stable in the opinion of the study doctor.
    • Women must be of non-child bearing potential

     

    STUDY DURATION:

    • Screening: 3 Visits will be required for screening
    • In Clinic Stay: 3 nights/4 days
    • Outpatient Visits: 10 visits
    • Total study duration: 192 days

     

    METHOD OF ADMINISTRATION:

    • Intravenously

     

    STUDY COMPENSATION:

    • Part 1 compensation up to $2648.00 for study participation time

     

    RECRUITMENT CONTACT:

    • Jenna at 651-724-0500 or jennal@prismresearchinc.com
  • HEALTHY: CLINICAL RESEARCH STUDY 2020 SAD

    PRISM RESEARCH

    Cohorts 1-3 and 5-7

    PURPOSE:

    • Phase 1 study to determine the safety and tolerability of a single dose of HU6 in healthy volunteers. HU6 is being developed to treat nonalcoholic steatohepatitis (NASH).

     

    GENERAL STUDY REQUIREMENTS Cohort 1-3, 6 and 7:

    • Males and Females between the ages 18-45 years old

    • Must be healthy and not taking any medications (birth control is acceptable)

    • Must have a BMI of 18.0 - 30.0

    • Must be a Non-smoker

    • Must not be claustrophobic or have intolerance of closed or small spaces

     

    COHORT 5

    • Must have BMI > 30.0 kg/m2, waist circumference > 41 inches

    • Medications will be reviewed on a case by case basis

     

    STUDY DURATION:

    • Clinic Visits: 1 Screening

    • In clinic stay: 3 consecutive nights/ 4 days

    • Follow Up: 1 in person follow up Day 5

    • Total Study Duration: 33 days (including screening window)

     

    STUDY DATES:

    • Multiple Admits: currently enrollong cohorts 4,5,6, 7

    10/29, 11/9, 11/11

    Cohort 5 Dates:

    November

     

    METHOD OF ADMINISTRATION:

    • Oral capsule

     

    STUDY COMPENSATION:

    Compensation for study participation may be provided for time and travel up to $1,100.00

     

    RECRUITMENT CONTACT:

    • Dayna 651-724-5047 or daynas@prismresearchinc.com

    Lindsay 651-368-3360 or lindsayd@prismresearchinc.com

    • Schedule a call: https://calendly.com/prism-recruitment/2020-phone-pre-screen

  • Kidney Impairment: Clinical Research Study 2009

    Renal Impairment Study

    Clinical RESEARCH study: 2009

     

    PRISM RESEARCH

      

    Purpose:

    •  To evaluate the safety, tolerability and pharmacokinetics of an investigational drug in healthy volunteers and volunteers with different levels of renal impairment.  The investigational drug being developed for the treatment of inflammatory disease.

     

    GENERAL STUDY REQUIREMENTS:

    •  Men and Women, between the ages of 18-75 with a BMI between 17.5 - 40
    •  Medical conditions and medications must be stable in the opinion of the study doctor

     

    STUDY DURATION:

    •  In Clinic Stay: 4 nights/5 days
    •  Return Clinic Visits: 3 (including 2 screening visits)
    •  Total study duration is up to 63 days

     

    METHOD OF ADMINISTRATION:

    •  Oral Dose

     

    STUDY COMPENSATION:

    • Compensation for Study Participation Time Up To: $1,785.00

     

    RECRUITMENT CONTACT:

     

  • Healthy Males and Females: Study 2022

    Preidentifying Volunteers NOW!  Schedule a call to discuss details: https://bit.ly/3dLZHD0

     

    HEALTHY MALES AND FEMALES: CLINICAL RESEARCH STUDY 2022

    PRISM RESEARCH

    PURPOSE:

    • To evaluate the bioequivalence of a capsule and tablet formulation of an investigational medication.

    GENERAL STUDY REQUIREMENTS:

    • Male and females between the ages 18-55 years old
    • Must be healthy and not taking any medications
    • BMI of 17.5-30.5
    • Non-smokers or occasional smokers and able to stop for duration of study

    STUDY DURATION:

    • Clinic Visits: 1 Screening and 1 follow up phone call
    • In clinic stay
      • Sequence 1 or 2: 8 nights/ 9 days- COMPLETED
      • Sequence 3 or 4: 5 nights/ 6 days
    • Total Study Duration: up to 70 days

    METHOD OF ADMINISTRATION:

    • Oral pills

    STUDY COMPENSATION:

    • Compensation for study participation may be provided for time and travel up to $1,550.

    RECRUITMENT CONTACT:

    • Lindsay 651-368-3360 or lindsayd@prismresearchinc.com

     


     

  • HEALTHY MALES AND FEMALES: CLINICAL RESEARCH STUDY 2019

    PURPOSE:

    To evaluate the safety and tolerability of BIO 300 for multiple clinical indications related to DNA damage and inflammation

    GENERAL STUDY REQUIREMENTS:

    • Men and women between the ages 18-64 years old
    • Must be healthy and not taking any medications (hormonal birth control is okay)
    • BMI of 18-32.0
    • Non-smokers

    STUDY DURATION:

    Single Ascending Dose Cohorts

      • 5 outpatient clinic visits, lasting 15 minutes - 1 hour(s)
        • 1 screening visits, 3 clinic visits consecutive days, 1 follow up visit

     

    Multiple Dose Cohorts

      • 10 outpatient clinic visits, lasting 15 minutes - 1 hour(s)
        • 1 screening visit, 8 clinic visits consecutive days, 1 follow up visit

     

    METHOD OF ADMINISTRATION:

    Dry Powder 

     

    STUDY COMPENSATION:

    Compensation for study participation provided for time and travel up to between $825.00 - $1,725.00

     

     

    RECRUITMENT CONTACT:

    Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 2028 Healthy Males and Females

    STUDY DURATION:

    • Clinic Visits: 1 Screening

    • In clinic stay: 3 consecutive nights/ 4 days

    • Follow Up: 1 in person follow up Day 6

     

     

    STUDY DATES:

    • Multiple Admits

    12/14, 12/15

     

     

    METHOD OF ADMINISTRATION:

    • Oral capsule

     

    STUDY COMPENSATION:

    Compensation for study participation between $850- $1,175

     

    RECRUITMENT CONTACT:

    • Dayna 651-724-5047 or daynas@prismresearchinc.com

  • HEALTHY: CLINICAL RESEARCH STUDY 2029

    HEALTHY: CLINICAL RESEARCH STUDY 2029

    PRISM RESEARCH

    PURPOSE:

    Evaluate the safety and tolerability of multiple doses of the study drug in combination with other drugs and alone in healthy volunteers.  The drug is being developed for the treatment of inflammatory diseases.

    GENERAL STUDY REQUIREMENTS:

    • Females and surgically sterile males between the ages 18-55 years old
    • Must be healthy and not taking any medications (birth control ok)
    • Must be a non-smoker for minimum 90 days
    • Must have a BMI of 19 - 30.0

    STUDY DURATION:

    • Clinic Visits: 1 Screening and 1 Covid-19 screen
    • In clinic stay:
      • Sequence AB: 17 consecutive nights/ 18 days
      • Sequence BA: 23 consecutive nights/24 days
    • 1 follow-up phone call

    Compensation for study participation provided for time and travel up to $7,625.00. You will be required to stay at Prism from 11/30 until 12/23. 

    For more information text/call Andy @ 651-332-1810 or andyh@prismresearchinc.com

     

     

     

     

     

     

     

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel